VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
UTHR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
UTHRUnited Therapeutics Corporation
$577.34$24.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksUTHRCash Flow

United Therapeutics Corporation (UTHR) Cash Flow Statement

28Y historyFree accessUpdated daily

Free cash flow margin fell from 48.6% in 2025Q1 to 15.1% in 2026Q3 as capex rose to 21.7% of revenue and $500.0M went to net acquisitions, suggesting capital deployment has displaced buybacks as the primary use of cash.

Income StatementBalance SheetCash FlowRatios

UTHR Cash Flow Statement

Annual statement

UTHR Cash Flow Statement

United Therapeutics Corporation (UTHR) cash flow statement — 28-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98
Cash from Operations1.43B1.56B1.33B978M802.5M598.2M755.7M-206.6M778.4M474.2M643.6M382.8M355.3M425.27M323.63M250.19M211.53M99.72M-49.2M48.95M49.39M43.17M20.78M-8.56M-22.26M-38.9M-31.11M-23.7M-9.6M
Operating CF Margin %-49.05%46.12%42.02%41.45%35.49%50.95%-14.26%47.82%27.49%40.26%26.12%27.57%38.07%35.33%33.67%35.03%26.96%-17.48%23.2%30.94%37.24%28.23%-16.05%-73.9%-678.66%-1518.35%-5925%-9600%
Operating CF Growth %20.04%17.64%35.7%21.87%34.15%-20.84%465.78%-126.54%64.15%-26.32%68.13%7.74%-16.45%31.41%29.35%18.28%112.12%302.71%-200.51%-0.89%14.41%107.75%342.68%61.53%42.78%-25.02%-31.29%-146.88%-
Net Income1.23B1.33B1.2B984.8M727.3M475.8M514.8M-104.5M589.2M417.9M713.7M651.6M340.1M174.56M304.44M217.87M105.92M19.46M-42.79M19.86M73.97M65.02M15.45M-9.97M-23.65M-37.29M-75.61M-33.5M-12.8M
Depreciation & Amortization96M85.6M72.5M53.2M51.3M49.9M49.9M45.9M35.9M31M31.6M32.9M32.2M31.26M27.14M20.54M17.92M11.39M4.54M957K1.46M2.41M2.28M2.33M3.13M3.51M-79.74K-1.3M0
Stock-Based Compensation157.3M147.7M144M39.1M106.8M138.5M163.8M45.4M-26.4M73.5M12.1M280.3M190.1M320.79M30.11M-15.71M113.94M101.02M28.7M48.7M000000000
Deferred Taxes197.8M97.7M0000000000185.11M104.34M136.23M81.43M41.92M-1.04M-34.39M-3.28M-37.05M-18.13M0000000
Other Non-Cash Items41.1M2M-24.3M-1.3M58.3M108.2M-35.9M-15.1M55.3M30.2M3.6M-379.9M-191.71M-93.36M33.89M57.33M6.64M20.18M-7.75M-15.57M16.31M2.11M1.64M2.14M11.4M2.06M42.83M9.3M2M
Working Capital Changes-293.3M-106.4M-60.2M-97.8M-141.2M-174.2M63.1M-178.3M124.4M-78.4M-117.4M-202.1M-200.5M-112.32M-208.19M-111.25M-74.81M-51.29M9.04M-4.2M-5.3M-8.25M1.42M-3.05M-13.14M-7.19M1.74M1.8M1.2M
Change in Receivables-50.9M-70.9M-400K-58.5M-21.7M-41.3M-6M24.4M121.4M-82.7M-21.7M-30.5M-35.7M-10.03M-23.99M-16.16M-23.45M-21.96M-2.33M-4.03M-8.87M-220K00-8.27M-196.7M000
Change in Inventory-99.9M-52.6M-46.9M-13.6M-13.4M-7.5M10.3M12.9M9.3M-500K-24.5M-6.8M-21M-12.39M-5.93M-16.05M-9.2M-9.06M-2.63M-2.34M-1.01M-3.46M-385K-1.2M-1.87M-4.04M-2.12M00
Change in Payables96.7M97.9M000000066.2M600K16.97M-6.75M7.51M-37.21M16.66M-2.73M-3.65M18.51M-1.07M000000000
Cash from Investing93M-551.3M417.2M-719.6M-811.5M-486.9M-738.5M-335.4M-820.6M-835.6M48.3M503.6M338.5M-294.97M-163.36M-121.33M-209.24M-160.52M-172.48M-21.71M-104.03M-71.28M-12.87M-47.54M120.36M-134.78M7.16M-24.1M-11.5M
Capital Expenditures-562.4M-520.5M-246.5M-230.4M-138.8M-120.8M-59.3M-83.7M-184.4M-86.3M-43.2M-49.79M-47.44M-31.91M-111.91M-35.98M-18.64M-95.4M-124.42M-38.66M-15.63M-6.12M-5.22M-7M-3.58M-687.29K-639.88K-2.3M-1M
CapEx % of Revenue17.64%16.35%8.57%9.9%7.17%7.17%4%5.78%11.33%5%2.7%3.4%3.68%2.86%12.22%4.84%3.09%25.79%44.2%18.33%9.79%5.28%7.09%13.13%11.89%11.99%31.22%575%1000%
Acquisitions00-30.5M-89.2M-1.5M00-20.5M-129.1M-60.3M-43.3M00-30.77M0-3.55M0-3.57M00000000-8.13M00
Investments-----------------------------
Other Investing1.28B1.85B-28.5M-23M3.5M02.4M0-46M8.3M0350M030.77M0013.9M-2.1M0000-179K4.18M-5.41M40K-3.87M-100K0
Cash from Financing-1.67B-1.15B-1.25B-11.9M75.4M44.8M-16.9M611.2M6.3M43.3M-497.7M-447M-576.6M-5.12M-169.14M-218.08M146.76M36.48M213M20.88M74.13M14.17M6.32M2.01M185K-2.88M206.61M59.3M22.9M
Debt Issued (Net)11.5M-300M-400M-100M00-50M600M0250M-8.8M-133.2M-177.8M-1.32M-999K-8.57M38.56M0-23K-10K242.01M-795K-774K-2.08M-60K-80K-58.52K1.1M0
Equity Issued (Net)-1.65B-816.9M-1.01B-13.8M-11.4M-10.8M-3.7M-2.1M0-250M-500M-394.5M-483.1M-42.44M-188M-212M00150M-67.06M-178.64M14.96M7.09M4.08M245K-2.8M206.51M58.4M22.9M
Dividends Paid0000000000000000000-29.6M000000000
Share Repurchases-2.06B-1B-1.01B-13.8M-11.4M-10.8M-3.7M-2.1M0-250M-500M-394.5M-483.1M-42.44M-188M-212M000-67.06M-193.09M0000-2.8M-4.07M00
Other Financing-39.6M-33.1M157.4M101.9M86.8M55.6M36.8M13.3M6.3M43.3M11.1M80.7M84.3M38.64M19.86M-5.04M108.2M36.48M63.05M58.34M10.76M00000159.42K-200K0
Net Change in Cash-151.2M-140.1M489.5M246.5M66.4M156.1M300K69.2M-35.9M-317.9M191.2M434.1M113.44M124.86M-8.65M-89.49M151.81M-29.1M-9.87M48.26M21.89M-13.41M14.22M-54.09M98.28M-176.56M182.66M11.5M22.9M
Free Cash Flow867.2M1.04B1.08B747.6M663.7M477.4M696.4M-290.3M594M387.9M600.4M333.01M307.86M393.36M211.72M214.22M192.89M2.22M-173.59M10.43M36.15M37.58M15.56M-15.57M-25.84M-39.59M-31.75M-26M-10.6M
FCF Margin %27.21%32.7%37.55%32.12%34.28%28.32%46.95%-20.04%36.49%22.48%37.55%22.72%23.89%35.22%23.11%28.82%31.94%0.6%-61.67%4.94%22.65%32.42%21.15%-29.18%-85.79%-690.65%-1549.57%-6500%-10600%
FCF Growth %-22.7%-3.69%44.54%12.64%39.02%-31.45%339.89%-148.87%53.13%-35.39%80.3%8.17%-21.73%85.79%-1.16%11.06%8573.2%101.28%-1765.1%-71.16%-3.81%141.52%199.97%39.76%34.73%-24.66%-22.13%-145.28%-
FCF per Share19.1421.7322.2815.0413.6810.0915.61-6.6313.508.6412.836.505.687.393.973.613.240.04-3.790.230.750.750.33-0.37-0.63-0.98-0.83-0.97-0.64
FCF Conversion (FCF/Net Income)0.70x1.17x1.11x0.99x1.10x1.26x1.47x1.98x1.32x1.13x0.90x0.59x1.04x2.44x1.06x1.15x2.00x5.12x1.15x2.46x0.67x0.66x1.34x0.86x0.94x1.04x0.41x0.71x0.75x
Interest Paid9.6M13.5M40.2M56M29.1M16.2M20.7M41M9.4M7.5M1.5M1M5.5M5.52M5.3M4.1M1.82M1.25M1.25M1.21M000000000
Taxes Paid165.6M313.3M400.6M332.5M275.7M153.3M92.8M120.2M102.7M346.9M362.4M293.3M195.6M142.14M101.5M46.51M22.68M23.93M1.63M1.55M000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrong
Balance SheetFortress
Cash FlowMixed
Top Statement Risk

Lumpy operating cash conversion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Conversion Swings Widely

According to reported quarterly figures, UTHR's operating cash flow to net income ratio ranged from 0.62 to 1.69 across the last ten quarters, with 2026Q3 at 1.19, indicating earnings quality that is timing-dependent rather than consistently cash-backed.

The ratio averaged near 1.1 over the period, meaning cash generation has broadly tracked profit, but the quarter-to-quarter dispersion is wide enough that single-period readings should not be relied upon. The 2025Q2 low of 0.62 and the 2026Q1 high of 1.69 are consistent with working capital timing, given the large swings in the working capital line, rather than a structural change in earnings quality. Investors should monitor whether conversion settles back toward the 1.0 to 1.2 band over the next several quarters.

Free Cash Flow Margins Compressing From Peak

Based on reported figures, UTHR's free cash flow margin fell from 48.6% in 2025Q1 to 15.1% in 2026Q3, as capital expenditure rose and operating cash flow lagged the earlier peak.

The decline reflects both a softer operating cash flow base and a higher capex load, with capex reaching $180.7M in 2026Q3 against roughly $75M to $100M in earlier 2025 quarters. The trend suggests the company's historically exceptional free cash generation is normalizing, which may indicate that the pipeline investment is absorbing a larger share of cash. Continued margin compression would warrant scrutiny of whether the spending is generating commensurate returns.

Rising Capital Intensity Tied to Pipeline

As reported in financial statements, UTHR's capex as a share of revenue climbed to 21.7% in 2026Q3 from 7.8% in 2025Q2, a material step-up in capital intensity for a business with historically light asset needs.

The increase is consistent with heavy investment in organ manufacturing and manufacturing infrastructure rather than maintenance of the treprostinil franchise, which carries modest physical asset requirements. Depreciation of $26.4M in the latest quarter remains far below capex, implying the asset base is expanding rather than being replaced. This pattern appears to reflect growth investment whose payoff is long-dated and unproven.

Acquisitions Absorb Cash Ahead of Buybacks

Based on UTHR's reported figures, net acquisition outflows totaled roughly $1.5B in 2026Q1 and $500.0M in 2026Q3, alongside a shift away from the earlier pattern of regular buybacks as the primary use of surplus cash.

The scale of recent acquisition outflows suggests management has redirected surplus cash toward external or pipeline assets, which may indicate a strategic move away from pure capital return. Dividends are absent in the reported periods, so shareholder returns depend entirely on repurchases, which have become less consistent. Whether these deployments generate adequate returns remains an open question warranting further investigation.

Cash Strength Masks Earnings Pressure

According to reported figures, UTHR's strong quarterly free cash flow in early 2026 coexists with an EPS decline of 20.3% year over year in 2026Q3, which may suggest the cash picture is flattered by working capital timing rather than underlying earnings momentum.

Stock-based compensation has been intermittently reported as zero, which may understate non-cash costs in some periods and should be treated as a data limitation rather than a conclusion. Strong operating cash flow in 2026Q1 at $463.3M appears inconsistent with the subsequent deceleration, reinforcing the view that timing effects drive much of the reported strength. Investors should not extrapolate the early-2026 cash figures as a run rate without confirming that working capital inflows are sustainable.

UTHR — Frequently Asked Questions

Quick answers to the most common questions about buying UTHR stock.

How much cash does United Therapeutics Corporation (UTHR) generate from operations?

United Therapeutics Corporation (UTHR) generated $1.56B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is United Therapeutics Corporation's free cash flow?

United Therapeutics Corporation (UTHR) generated $1.04B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is United Therapeutics Corporation's capital expenditure (CapEx)?

United Therapeutics Corporation (UTHR) spent $520.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does United Therapeutics Corporation distribute cash to shareholders?

In 2025, United Therapeutics Corporation (UTHR) spent $1.00B on share repurchases. This shows the company's commitment to returning capital to its equity investors.